Delivery Order SPE2DB24D2205-SPE2DB25FEJCC
- Not listed
- The Defense Logistics Agency awarded a $3,425.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used to treat idiopathic pulmonary fibrosis. The contract, awarded on July 21, 2025, with an ultimate completion date of August 11, 2025, was competitively awarded without set-aside provisions. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $17,129.75 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Esbriet 801 mg, a pharmaceutical treatment primarily used for idiopathic pulmonary fibrosis. This firm fixed-price delivery order, which was competitively awarded without set-aside provisions, is scheduled for completion by September 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, leveraging the company's...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used in the treatment of idiopathic pulmonary fibrosis. The contract, awarded on September 23, 2025, with an ultimate completion date of October 15, 2025, represents a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical will be...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 90 tablets of Esbriet 801 mg, a pharmaceutical product for pulmonary fibrosis treatment. This competitive award was issued on June 20, 2025, with a completion date of July 14, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract contains no set-aside designation, indicating it was awarded through open competition....
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp on June 27, 2025, for 90 tablets of Esbriet 801 mg, a pharmaceutical treatment for idiopathic pulmonary fibrosis. This firm fixed-price delivery order, with an ultimate completion date of July 21, 2025, was competitively awarded without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,425.95 for 90 tablets of ESBRIET 801 MG, a pharmaceutical product used in the treatment of idiopathic pulmonary fibrosis. This competitively awarded, firm fixed-price delivery order was issued on August 18, 2025, with an ultimate completion date of September 9, 2025. The contract carries no set-aside designation, indicating it was competed among eligible vendors meeting federal procurement standards....
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used primarily for pulmonary fibrosis treatment. This competitively awarded, firm fixed-price delivery order has a ceiling value of $6,851.90 and is scheduled for completion by October 3, 2025. The contract specifies performance at AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate headquarters. No...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used in the treatment of idiopathic pulmonary fibrosis. This non-set-aside competitive award was issued on June 16, 2025, with an ultimate completion date of July 9, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract action...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $3,425.95 delivery order on August 13, 2025, for 270 tablets of Esbriet 267 mg, a pulmonary fibrosis medication. This competitively awarded, firm fixed-price contract contains no set-aside designation and is scheduled for completion by September 4, 2025. The pharmaceutical supply will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency's Medical Supply Chain for 270 tablets of Esbriet 267 mg on September 23, 2025, with a ceiling value of $6,851.90 and an ultimate completion date of October 15, 2025. The contract employs firm fixed-price pricing with no set-aside designation, indicating competitive award. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEJCCDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,851.90 for 270 tablets of Esbriet 267 mg, a pharmaceutical product used in the treatment of idiopathic pulmonary fibrosis. The contract is firm fixed price with no set-aside designation and was awarded on September 25, 2025, with an ultimate completion date of October 17, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to military healthcare systems and other federal government healthcare customers worldwide. The competitively awarded IDC demonstrates AmerisourceBergen's established capability to meet federal pharmaceutical procurement requirements across multiple therapeutic domains and delivery scales.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.9k | 9/25/25 |